DUBLIN--(BUSINESS WIRE)--The "World Market for Biopharmaceutical Drug Delivery Device Technology" report has been added to ResearchAndMarkets.com's offering.
The total market for biopharmaceutical drug delivery is very complex and shifting due to technological advancements.
Though the market to date has been dominated by injectable administration, injections are not the first choice among patients and compliance is an ongoing issue.
Further, as the majority of new entities in development are biologics requiring advanced drug delivery, manufacturers of devices have been busy developing new innovations that will meet the current needs of biopharmaceuticals already on the market and future biopharmaceuticals in development.
The development of safe, efficient, cost-effective needle-free devices has long been a major goal of the drug delivery community. The technology continues to advance as needle-free company marketers are evolving, searching for a strategy that will achieve commercial success.
Companies have invested in new device models that incorporate design enhancements and improved engineering. The report discusses selected needle-free Injector systems, touching on implants, pumps, microfluidic technology, and transdermal technology.
World Market for Biopharmaceutical Drug Delivery Device Technology examines biopharmaceutical drug delivery technologies currently in development. These include:
- Microsphere Technology
- Targeted Technology
- Intracellular Delivery Technology
- MicroChip Technology
- Protein-Coated Microcrystal Technology
- Needle-Free Delivery Development
- Bolus Injectors
- Large Volume Wearable Injectors
- Combination Products
- Arrayed Microinjectors
Many of the drug development companies have products in development that utilize their proprietary drug delivery systems.
The number of companies providing biopharmaceutical drug delivery platforms continues to proliferate.
The biopharmaceutical drug delivery device industry is comprised of companies seeking to develop novel alternatives to existing delivery systems, enhancements to existing systems, commercially enabling delivery systems that provide viable alternatives for biotherapeutics that are not fully developed and marketed because there are limited practical means of administration.
Key Topics Covered
1. Executive Summary
3. Biopharmaceuticals - Drug Delivery Technology
4. Biopharmaceuticals - Alternative Routes of Drug Delivery
5. Trends and Drug Delivery Developments
6. Market Size and Growth
7. Company Profiles
- 3M Pharmaceuticals
- Alkermes Inc.
- Antares Pharma
- Ascendis Pharma A/S
- Becton Dickinson and Company (BD)
- Catalent Pharma Solutions
- Credence MedSystems
- D'Antonio Consultants International
- Enable Injections Inc.
- Halozyme Therapeutics Inc.
- InnoCore Pharmaceuticals Inc.
- Inovio Pharmaceuticals Inc.
- Insulet Corporation
- Intarcia Therapeutics Inc.
- Ligand Pharmaceuticals Inc.
- Medical International Technologies
- Medtronic Inc.
- Micron Biomedical
- Mystic Pharmaceuticals
- Nektar Therapeutics
- Pharmajet Inc.
- Portal Instruments Inc.
- SHL Group
- Valeritas Inc.
- West Pharmaceutical Services Inc.
- Ypsomed AG
For more information about this report visit https://www.researchandmarkets.com/research/dzx6s8/the_worldwide?w=4